BOCH
ASBPW

Blue Owl Capital Holdings’s Aspire Biopharma Warrant ASBPW Stock Holding History

Blue Owl Capital Holdings’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Hold
50,000
– – ﹤0.01% 75
2025
Q4 		$1K Hold
50,000
– – ﹤0.01% 75
2025
Q3 		$1.5K Hold
50,000
– – ﹤0.01% 68
2025
Q2 		$2.23K Hold
50,000
– – ﹤0.01% 70
2025
Q1 		$3.5K Hold
50,000
– – ﹤0.01% 69
2024
Q4 		$2.5K Hold
50,000
– – ﹤0.01% 74
2024
Q3 		$2K Buy
+50,000
New +$2.38K ﹤0.01% 106

Other funds holding ASBPW

MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Blue Owl Capital Holdings's ASBPW Position: Q1 2026 in Review

Blue Owl Capital Holdings held its Aspire Biopharma Warrant (ASBPW) position steady in Q1 2026 at 50,000 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #75.

Blue Owl Capital Holdings first reported a position in ASBPW in Q3 2024 and has held it in 7 quarters since. The position peaked at $3.5K in Q1 2025. 29 funds tracked by Wall St. Rank hold ASBPW as of Q1 2026.

  • Blue Owl Capital Holdings held 50,000 shares of Aspire Biopharma Warrant worth $1K as of Q1 2026.
  • Blue Owl Capital Holdings left its Aspire Biopharma Warrant share count unchanged in Q1 2026.
  • Aspire Biopharma Warrant made up ﹤0.01% of Blue Owl Capital Holdings's portfolio in Q1 2026, its #75 holding.
  • Blue Owl Capital Holdings first reported a position in Aspire Biopharma Warrant in Q3 2024 and has held it in 7 quarters since.
  • Blue Owl Capital Holdings's Aspire Biopharma Warrant position peaked at $3.5K in Q1 2025.
  • 29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.